EndogenX is based in Los Gatos, California, and is engaged in developing, acquiring, and commercializing novel pharmaceutical, therapeutic, and diagnostic products/applications worldwide.

Our strategy is to minimize regulatory hurdles so that it can significantly reduce its time to market and commercialization.

EndogenX has a pipeline of branded pharmaceutical and botanicals which will be made commercially available worldwide. The initial three products serve the estimated $2.8 billion U.S. chronic wound care and $25 billion super antibiotic market.

Each of the products in our Product Pipeline are poised to enter markets with revenue potential from $0.5 to $10 billion U.S. annually.